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In its 1980 benzene decision [Industrial Union Department, ALF-CIO v. American Petroleum Institute,
448U.S. 607(1980)], theSupremeCourtruledthat"beforehecanpromulgateanypermanenthealthorsafety
standard, the Secretary [of Labor] is required to make a threshold finding that a place of employment is
unsafe-inthesensethatsignificantrisksarepresentandcanbelessenedbyachangeinpractices" (448U.S.
at 642). The Occupational Safety and Health Administration (OSHA) has interpreted this to mean that
whenever possible, it must quantify the risk associated with occupational exposure to a toxic substance at
the current permissible exposure limit(PEL). IfOSHAdetermines thatthere is significant riskto workers'
health at its current standard, then it must quantify the risk associated with a variety of alternative
standards to determine at what level, if any, occupational exposure to a substance no longer poses a
significant risk.
For rulemaking on occupational exposure to 1,3-butadiene, there are two studies that are suitable for
quantitative risk assessment. One is a mouse inhalation bioassay conducted by the National Toxicology
Program (NTP), andthe other is arat inhalation bioassay conducted by Hazelton Laboratories Europe. Of
the four risk assessments that have been submitted to OSHA, all four have used the mouse and/or rat data
with a variety of models to quantify the risk associated with occupational exposure to 1,3-butadiene. In
addition, OSHA hasperformed its own risk assessmentusingthe female mouse and female rat dataandthe
one-hit and multistage models. While these risk assessments differ'in the risks predicted at low doses, they
all support OSHA's preliminary determination that there is significant risk of cancer from occupational
exposure to1,3-butadiene atthecurrent OSHAPELof1000ppm. OSHAplans topublish aproposal torevise
the current 1,3-butadiene standard. In addition, OSHA will publish a request for public comment on the
proposal. OSHA's final standard will be based on its evaluation ofthe public record and will be guided by
significant risk determination.
The Occupational Safety and Health Act of1970 spells
out the mandate ofthe Occupational Safety and Health
Administration (OSHA) for assuring safe and healthful
working conditions for working men and women (1). In
section 6(b)(5) of the Act, Congress directed that the
Agency, "in promulgating standards dealing with toxic
materials or harmful physical agents, . . . shall set the
standard which most adequately assures, to the extent
feasible, on the basis ofthe best available evidence, that
no employee will suffer material impairment ofhealth or
functional capacity even ifsuch an employee has regular
exposure to the hazard dealt with by such a standard for
the period ofhis workinglife." In Section 3(8), Congress
defined "occupational safety and health standard" as "a
standard which requires conditions, or the adoption or
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use of one or more practices, means, methods, oper-
ations, or processes reasonably necessary or appropri-
ate to provide safe or healthful employment orplaces of
employment."
Based onthe beliefthat any exposureto acarcinogen,
regardless of the level, is not safe, OSHA originally
interpreted Congress's directive as meaning that occu-
pational exposure to carcinogens should be regulated
down to the lowest feasible level. In 1980, the Supreme
Court rejected this interpretation ofthe Act in its ben-
zene decision (2). The Court ruled that "before he can
promulgate any permanent health or safety standard,
the Secretary [ofLabor] isrequired tomake athreshold
finding that a place of employment is unsafe-in the
sense that significant risks are present and can be less-
ened by a change in practices" (448 U.S. at 642).
The Supreme Court did notdefine "significantrisk" in
its ruling, but it did offer some guidelines. The Court
wrote that "ifthe odds are one in a billion that a person
will die from cancer by taking a drink of chlorinated
water, the risk clearly could not be considered signifi-GROSSMAN AND MARTONIK
cant. On the other hand, ifthe odds are 1 in a 1000 that
regular inhalation of gasoline vapors that are 2% ben-
zene will be fatal, a reasonable person might well con-
sider the risk significant and take appropriate steps to
decrease or eliminate it" (448 U.S. at 655). The Court
went on, however, to say that "OSHA is not required to
support its finding that a significant risk exists with
anything approaching scientific certainty ... so long as
they are supported by a body of reputable scientific
thought, theAgencyisfreetouse conservative assump-
tions interpreting the data with respecttocarcinogenic-
ity risking error on the side of over-protection rather
than under-protection" (448 U.S. at 656).
OSHA has interpreted the Supreme Court's ruling to
meanthatitmustperformquantitative riskassessments
whenever possible in order to determine whether occu-
pationalexposuretoatoxicsubstanceposesasignificant
risk to workers. IfOSHA determines that a significant
riskexists, thenitmustquantifytheriskassociatedwith
a variety ofalternative standards to determine at what
level, if any, occupational exposure to a substance no
longer poses a significant risk.
The current OSHA standard for 1,3-butadiene is 1000
parts per million (ppm) determined as an 8-hr time-
weighted average (3). Adopted in 1971, this standard
was aimed at preventing irritation and necrosis. Since
thattime, twoanimalbioassays have shownthat 1,3-bu-
tadiene exposure induces cancer in rodents. The two
studies, an inhalation bioassay conducted by the Na-
tionalToxicologyProgram(NTP)usingB6C3F1 mice(4)
and aninhalationbioassay conducted by Hazelton Labo-
ratories Europe (HLE) using CD rats of the Sprague-
Dawley strain (5), demonstrated a dose-response re-
lationship between exposure and carcinogenesis. In ad-
dition to this evidence of the carcinogenicity of
1,3-butadiene, four epidemiological studies have been
conducted that show elevated death rates due to lym-
phohematopoietic cancers among workers exposed to
1,3-butadiene (6-9).
Following the Supreme Court's Benzene decision,
OSHA must first determine whether workers face sig-
nificant riskofcancer atexposures of1000ppmbeforeit
can consider reducing the current standard. In order to
make this determination, OSHA reviews the public rec-
ord and evaluates research and analyses on the occu-
pational risk of1,3-butadiene exposure. OSHA uses the
research of others to develop its own preliminary as-
sessment of risk. This assessment is published with a
proposal for a revised standard. At that time, OSHA's
assessment may be evaluated by scientists and inter-
ested parties outside of the Agency, and anyone may
comment on the assessment.
For the rulemaking on 1,3-butadiene, five risk as-
sessments have been submitted. Two ofthese are from
the U.S. EnvironmentalProtectionAgency; oneis from
the Office ofToxic Substances (OTS) (10), and the other
is from the Carcinogenicity Assessment Group (CAG)
(11). A third risk assessment was performed under
contract to OSHA by ICF/Clement Association (ICF)
(12), and a fourth was performed under contract to the
ChemicalManufacturers AssociationbyEnviron Corpo-
ration (13). The National Institute of Occupational
Safety and Health (NIOSH) has recently submitted a
fifth risk assessment that was performed by D. Hattis
andJ. Wasson at the CenterforTechnology, Policy and
Industrial Development at the Massachusetts Institute
of Technology (14). OSHA is currently reviewing this
assessment which is a pharmocokinetic/mechanism-
based analysis ofthe carcinogenic risk of1,3-butadiene.
All of these risk assessments relied on the animal
bioassay data for quantifying carcinogenic risk. While
there is less uncertainty in extrapolating risks from
human data, none ofthe available epidemiological stud-
ies provide adequate exposure data for such an assess-
ment. Therefore, risk assessments must rely upon the
animal data for their analyses. Both bioassays have the
advantage that the route ofexposure is the same as the
one found in occupational settings (i.e., inhalation), the
animals were exposed to at least two different levels of
the test substance, and concurrent controls were used.
In addition, data on the absorption of 1,3-butadiene in
both mice and rats are available and can be used to
estimate internal dose (15).
Extrapolating risks from animals to humans entails
five steps before risks may be estimated. Choices made
by a risk assessor at each ofthese steps will affect the
outcome of a risk assessment, and therefore OSHA's
evaluation ofa quantitative risk assessment centers on
these choices. All ofthe risk assessments submitted to
OSHA differ in the choices made.
The first step in performing a quantitative risk as-
sessment entails choosing a data set for low-dose ex-
trapolation. OTS and ICF considered only the male and
female mice; CAG used the males and females of both
species; and Eviron used the male and female rats but
only the male mice.
Although exposure levels are determined in the de-
sign of a bioassay, the risk assessor must choose an
appropriate measure ofexperimental dosewhenextrap-
olating risks across species. OTS and ICF measured
dose in parts per million, but ICF adjusted for absorp-
tion while OTS did not. Both adjusted for early termin-
ationofthestudy, butOTSmadethisadjustmenttodose
while ICF made this adjustment to risk. CAG and En-
vironmeasured dose inmilligrams perkilogram perday
and adjusted experimental dose for absorption.
The risk assessor must also choose an appropriate
measure of response. It is in this respect that the risk
assessments reviewed by OSHA differ most. While all
the risk assessments considered pooled tumorincidence
asits measureofcarcinogenicresponse, different tumor
incidences were used to formthepool. This is especially
true for the analyses ofthe rat data; each person count-
ing tumors from the individual pathology reports
seemed to have a different estimate oftumorincidence.
Pooled tumor incidence among the mice, however, also
differed from risk assessment to risk assessment. OTS
usedlife-tableadjustedincidence. CAGandICFusedall
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tumors reported by NTP as occurring at a statistically
significantly elevated rate in exposed mice, but ICF
excluded papillomas of the forestomach. In addition to
looking at pooled tumor incidence, OTS and ICF con-
sidered site-specific tumor incidence as a measure of
carcinogenic response in the mouse.
The fourth step in performing a quantitative risk
assessment is to convert occupational dose into units
comparable to those in which experimental dose is mea-
sured. While each risk assessment used different as-
sumptions and exposure scenarios, OSHA assumed that
the average worker weighs 70 kg, breathes 9.6 m3 ofair
during an 8-hr shift, and works 8 hr/day, 250 days/year,
for 45 out of 74 years of life.
Occupational dose must also be adjusted for absorp-
tion. OTS assumed 100% absorption in humans regard-
less ofdose, and CAG and Environ assumed 54% absorp-
tion in humans regardless of dose. ICF assumed that
absorption in humans varied with dose at the same rate
it varied with dose in the mice.
Finally, in any quantitative risk assessment, the
choice of mathematical model used for extrapolating
risks observed in the high-dose range to risks associated
with exposure at lower doses will effectthemagnitude of
predicted risks. Models fall into two types: mechanistic
and tolerance distribution. The most popular mecha-
nistic model is the multistage model, based on a theory
proposed by Armitage and Doll in 1961 (16). The multi-
stage model is based on the biological assumption that
cancer is induced by carcinogens through a series of
stages. The one-hit model is a special case of the multi-
stage model and is based on the assumption that there is
only one stage in the carcinogenic process. OTS, CAG,
and ICF used only the multistage model to extrapolate
risks. Tolerance distribution models, such as the probit
model and logit model, attempt to describe the dis-
tribution oftolerances (i.e., exposure levels below which
no response occurs) in an exposed population. Environ
considered some ofthese models in addition to the multi-
stage model.
After OSHA reviewed the submitted risk assess-
ments, it performed its own preliminary analysis ofthe
risk associated with occupational exposure to 1,3-bu-
tadiene. Like the others, OSHA has relied on the animal
data in its assessment. Experimental dose was mea-
sured in miligrams perkilogram perday and adjusted for
absorption. Risks were derived using both pooled tumor
and site-specific tumor incidence data with the multi-
stage model. OSHA has consistently evaluated several
models when performing quantitative risk assessments,
but it has shown a preference for the multistage model.
The Agency hasjustified this preference on the grounds
that the multistage model has the best empirical and
theoretical justification for use in making "best esti-
mates" oflikely risk at specific doses. Furthermore, the
multistage modelis aconservative, nonthreshold model,
and OSHA believes that its application in quantitative
risk assessment is prudent public health practice.
Table 1 presents risk estimates from OSHA's pre-
Table 1. Estimates of cancer risk to workers with lifetime
occupational exposure to 100 ppm 1,3-butadiene.a
Source Date Model Risk per 10,000
OSHA Pooled female Multistage 180
mouse tumorsb (1300)
OSHA Female mouse Multistage 443
hemangiosarcomas (610)
OSHA Pooled female One-hit 1272
rat tumorsc (1685)
OTS Pooled male One-hit 8843
mouse tumors (9683)
OTS Pooled female One-hit 5752
mouse tumors (6740)
OTS Male mouse One-hit 3298
hemangiosarcomas (4347)
CAG Pooled male and Multistage 7930
female mouse tumorsd (8597)
CAG Pooled male Multistage 208
rat tumors (610)
CAG Pooled female One-hit 4595
rat tumors (5563)
ICF Pooled male One-hit 10,000
mouse tumorsc (10,000)
ICF Pooled female Multistage 10,000
mouse tumors (10,000)
Environ Pooled male Hartley-Sielken 3730
mouse tumorsb (4260)
Environ Pooled male Multistage 210
rat tumorsf (682)
Environ Pooled male f Weibull 154
rat tumors (571)
Environ Pooled male Mantel-Bryan 559
rat tumorsf (847)
Environ Pooled female Multistage 575
rat tumorsg (794)
Environ Pooled female Weibull 560
rat tumorsg (763)
Environ Pooled female Mantel-Bryan 730
rat tumorsg (1040)
Abbreviations: OSHA, OccupationalSafetyand HealthAdministra-
tion; OTS, Office ofToxicSubstances; CAG, Carcinogenic Assessment
Group; ICF, ICF/Clement Association; Environ, Environ
Corporation.
aRisk estimates are the maximum likelihood estimates (MLEs).
Numbers inparentheses are the 95% upperconfidence limits (UCLs).
bIncidence of lymphoma excluded from pooled tumor incidence.
cHigh-dose group dropped from the analysis.
dMaximum likelihood estimates (MLE) and upper confidencelimits
(UCL) arethegeometricmeanoftheMLEsand UCLsestimatedfrom
male mouse data and female mouse data.
eModel is the Hartley-Sielken time-to-tumor model.
fIncidence ofZymbal gland carcinoma excluded from pooled tumor
incidence.
glncidence ofmammary fibroadenoma excluded from pooled tumor
incidence.
liminaryanalysis aswell asfromtheriskassessmentsby
OTS, CAG, ICF, and Eviron. Estimates are presented
as deaths per 10,000 for occupational exposure to 100
ppm-a level 10 times lower than the current OSHA
standard. These numbers were either calculated in the
risk assessments submitted to OSHA or derived from
those risk assessments. Presented are those risks asso-
ciated with exposure scenarios most closely resembling
the scenario chosen by OSHA.
In their risk assessments, OTS and ICF presented
only the 95% upper confidence limits (UCLs) for a vari-
ety of exposure scenarios. OSHA calculated the maxi-
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mum likelihood estimates (MLEs) associated with these
95% UCLs for exposure of8 hr/day, 240 days/year. For
OTS, exposure was for 40 out of 70 years; for ICF,
exposure was for 45 out of 70 years.
CAG focused its risk assessment on estimating the
unitriskassociatedwith 1,3-butadiene exposure. OSHA
derived estimates ofriskfromthe CAGriskassessment
using the equality 1 ppm = 2.25 mg/m3 and CAG's
assumptions that exposure occurred 8 hr/day per day,
240 days/year, for 45 out of70 years; that a 35-g mouse
breathes 0.043 m3 ofair/day; that a0.70-kgratbreathes
0.354 m3 ofair/day; and that absorption at low doses is
54%. Risks were estimated usingthe computerprogram
GLOBAL 82(17). Following CAG, OSHAcalculated the
geometric mean ofthe MLEs derived individually from
the male mouse data and the female mouse data. The
same was done for the UCLs. CAG reasoned that be-
cause response was so similar between male and female
mice, the geometric mean ofthe risks was an appropri-
ate estimate. While CAG adjusted its estimate of unit
risk for early termination of the NTP study, the num-
bers in Table 1 were not adjusted.
Table 1 shows that regardless ofwhich animal bioas-
sayisused, howtheexperimental oroccupationaldoseis
calculated, what the measure of carcinogenic response
is, and anyother adjustments made to the data, the risk
associated with occupational exposure to 100 ppm
1,3-butadiene overaworkinglifetime iswellinexcess of
the 1 per 1000 cited by the Supreme Court as con-
stituting significant risk. This exposure levelis 10times
lower than the current OSHA standard. The highest
risks are predicted by ICF. The ICF estimates exceed
100% risk because of the adjustment made for early
termination of the study. The lowest risk, 154 per
10,000, was predicted by Environ usingthe mechanistic
Weibull model applied to the male rat pooled tumor
incidence data.
OSHA has preliminarily stated that occupational ex-
posure to 1,3-butadiene poses a significant risk. In addi-
tion to demonstrating a health need for a standard,
however, OSHA's standards must be economically and
technologicallyfeasible; tothatend, ithascontractedfor
an economic and engineering survey of the industries
affected by the standard. Given preliminary reports of
feasibility, OSHAisproceedingwiththepublication ofa
proposal for a revised standard. Following publication,
there will be a comment period and then informal hear-
ings will be held. OSHA's final standard will be based
upon its evaluation of the public record and will be
guided by the Supreme Court's Benzene decision on
significant risk determination.
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